The Company holds various equity investments, which are recorded in Other assets on our Condensed Consolidated Balance Sheets. The following table summarizes our investment balances:


(in thousands)	June 30, 2026		December 31, 2025
Equity investments under the equity method of accounting	$	1,376	$	753
Equity investments without readily determinable fair values	21,767		21,712

Total equity investments	$	23,143	$	22,465

As of December 31, 2025, the Company owned 49% of NAMI’s common stock. In February 2026, the investee issued additional shares to another equity investor, which diluted our ownership share to 34.3% of the joint venture's common stock. The Company recognized a gain on the investee’s share issuance of $2.6 million, reported in Other (loss) income, net for the six months ending June 30, 2026. The gain related to the difference between our share of the proceeds from the additional investment and the impact of the dilution on the carrying value of our investment.

In December 2024, the Company entered into a short-term, non-interest bearing loan agreement with NAMI whereby NAMI borrowed $2.0 million to finance its working capital and capital expenditures requirements. The loan originally matured on June 30, 2025. During the quarter ended September 30, 2025, the parties amended the loan agreement to extend the maturity date to June 30, 2026, and increase the total related party note receivable to $4.4 million. NAMI did not repay the note receivable as of June 30, 2026 and the note is expected to be amended to extend the maturity date to December 31, 2026. The carrying value of the related party note receivable is $4.4 million as of June 30, 2026 and is recorded within Prepaid expenses and other current assets on our Condensed Consolidated Balance Sheets.

Additionally, during the three and six months ended June 30, 2026 and 2025, the Company entered into related party transactions with NAMI in the ordinary course of business. During the three and six months ended June 30, 2026, the Company recorded sales to NAMI of $0.5 million and $0.6 million, respectively. As of June 30, 2026, the outstanding related party receivable balances attributable to our sales with NAMI were not material.

During the three and six months ended June 30, 2026 and 2025, the Company entered into related party transactions with Enhatch Inc. ("Enhatch") in the ordinary course of business. During the three and six months ended June 30, 2026, the Company made purchases from Enhatch of $0.5 million and $0.9 million, respectively. As of June 30, 2026, the outstanding related party payable balances attributable to our purchases from Enhatch were not material.

Additionally, during the three and six months ended June 30, 2025, the Company entered into related party transactions with NAMI and Enhatch, including purchases and sales, but the transactions and related balances payable or receivable were not significant.

In February 2025, the Company provided financing of $1.0 million to Hull Legacy Media Corporation, a production company co-owned by Charles W. Hull, EVP, Chief Technology Officer for the Company's Regenerative Medicine business and a related party of the Company. The financing is recorded in Other assets on our Condensed Consolidated Balance Sheets as of June 30, 2026 and December 31, 2025.